stockportfolio.pro
Crescent Biopharma, Inc. (CBIO)
Healthcare · Biotechnology · NasdaqCM
Crescent Biopharma, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18,500 | $0 | $0 | $0 | $10.16M | $1.16M | $75,000 | $10,000 | $0 | $10.84M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-31.81M | $-33.28M | $-48.27M | $-57.89M | $-51.03M | $-63.43M | $-46.69M | $-36.90M | $-37.88M | $-153.94M |
| Net margin | -171945.1% | — | — | — | -502.1% | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
Source: Crescent Biopharma, Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Explore 14 years of Crescent Biopharma, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CBIO in your portfolio →
Crescent Biopharma, Inc. financial history by metric
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Crescent Biopharma, Inc. — frequently asked questions
What is Crescent Biopharma, Inc.'s revenue?
Crescent Biopharma, Inc. (CBIO) reported revenue of $10.84M for fiscal year 2025, according to its SEC filings.
Is Crescent Biopharma, Inc. profitable?
No — CBIO reported a net loss of $-153.94M in fiscal 2025.
What is CBIO's P/E ratio?
Crescent Biopharma, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Crescent Biopharma, Inc. growing?
CBIO's revenue grew at roughly 1.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Crescent Biopharma, Inc. have?
As of fiscal year 2025, CBIO carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Crescent Biopharma, Inc.'s market cap?
Crescent Biopharma, Inc. (CBIO) has a market capitalization of about $505.17M, based on the latest data in our nightly-refreshed cache.
When does Crescent Biopharma, Inc.'s fiscal year end?
CBIO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Crescent Biopharma, Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.